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accessible. In settings where with no VL and genotypic resistance
guided, TDF/3TC(or FTC)/LPv/r may be a suitable option.
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With nearly eighty percent of patients not receiving appropriate
are in Sub Saharan Africa, TMU likely constitutes a useful tool in
roviding large scale up HIV testing, biological monitoring, treat-
ent and care and should be integrated into national HIV control
rogrammes.
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CD4 testing has traditionally been performed using a ﬂow
ytometer. In resource limited settings such testing requires a lab-
ratory, a relatively expensive instrument, a trained technician and
s associated with signiﬁcant loss to follow up as the patient has to
eturn for results.
The semi-quantitative Burnet CD4 test has been speciﬁcally
esigned for point of care use, performed with ﬁnger-prick blood,
ithout requiring any instrument or cold chain, by a health care
orker with minimal training. The results are available within 40
inutes. The test detects full-length CD4 protein associated with
-cells, and excludes CD4 on monocytes and soluble CD4 protein
n blood. The Burnet CD4 POC tests have been designed with an
nitial cutoff of 250 CD4/l (to provide a safety margin above the
reatment cutoff of 200 CD4/l) or a second generation test with
cut-off of 350 cells/ l, in keeping with recent WHO recommen-
ations. Early external validation indicates that the test is accurate
assessed by mis-classiﬁcation) when compared to ﬂow cytome-
ry. The test is anticipated to improve access to ART and loss to
ollow-up associated with having to return for results.
The Alere PIMATM POC CD4 test has recently been released.
t has a throughput of 20 tests+ per day, with a 20-30 minute
urnaround timeand requiresno cold chain. It requires adevice that
s portable andperformswellwhencomparedwithﬂowcytometry.
Even in resource-constrained settings, it is generally agreed that
iral load testing is essential for accurate and early detection of a
oor response to ART. Identifying treatment failure early enables
atient adherence counseling and may permit patients to continue
n 1st-line cART, avoiding unnecessary switches to more expen-
ive 2nd-line regimens. Current HIV viral load testing methods
sing nucleic-acid ampliﬁcation are expensive, require sophisti-
ated equipment and signiﬁcant technical expertise and dedicated
aboratory facilities to prevent contamination,making themgener-
lly unsuitable forwidespread use in resource-constrained regions.
ncreased access to ART has highlighted the need for suitable low
ost viral load testing.
Cavidi ExaVirTMLoad v 3 is a low cost, relatively technically
imple HIV viral load assay based on reverse transcriptase quantiﬁ-
ation. The assay has a sensitivity of about 200 copies/ml, detects
ll HIV-1 and HIV-2 variants and results correlate well with Roche
OBASAmplicorTM assay.nfectious Diseases 16S (2012) e2–e157
There are several other POC CD4 (eg Zyomyx) and VL assays (eg
SAMBATM) under development that may be available in the next
few years; preliminary information will be provided.
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HAART inresource-limitedsettings(RLS):Approximately>80%
of 34 million HIV-infected patients were living inlow- and middle-
income countries, andat least 6.6 million were on HAART. Most
patients in RLS are treated with NNRTI-based regimen, nevirap-
ine+3TC+AZT or d4T in particular. Several studies either in Africa
or Asia have shown the viral success rate (plasma VL<50-400 c/ml)
was varied from 70%-90% (ITT analyses). The two most common
causes of treatment failure are non-adherence and drug-related
toxicity. Other factors including late diagnosis with advanced dis-
ease, very low CD4 cell counts and high viral load at baseline. In
most RLS, only CD4 count is available for treatment monitor, VL
and drug resistance genotypic tests are not accessible due to the
cost constraint. As a result, HAART failure has therefore been asso-
ciatedwith a verymuchdelayed in detecting failure comparedwith
the use of pVL as a monitoring test.
Drug resistance: Extensively exposed to the failing regimenwill
lead to more cross resistance. Early virologic failure(<6 months),
only 3TC or FTC resistance (M184V) and or NNRTI-resistance will
be detected. In contrast, late failure will result to an accumulation
of thymidine-analog mutations (TAMs) and eventually to a cross
resistance to both the NNRTI and NRTI classes.
Treatment options after NNRTI failure: The principle in select-
ing a new second-line option is to use ideally 3 new active ARVs in
the regimen. In reality, ARV options are very limited and also DR
genotypic test is not available to guide for active ARV selection.
Recently only one randomized trial, HIV-STAR has been reported.
In this study, almost all patients had 3TC and NNRTI-resistance.
A half had any of TAMs (TAM2:TAM1 3:1). The results showed a
signiﬁcant inferior of mono-LPV/r compared with when in combi-
nation with TDF/3TC (61% vs 83%, p<0.01). Thus mono-LPV/r is not
recommended.
Conclusions: Expanded access to HAART is essential to ﬁght
against the AIDS epidemic, however to early detect poor adherence
and treatment failure, it is anurgentneed toalsomakingpVLwidely
